The American Journal of Medicine
Volume 118, Issue 12 , Pages 1414.e21-1414.e27 , December 2005

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy

References 

  1. Ritz E , Rychlik I , Locatelli F , Halimi S . End-stage renal failure in type 2 diabetes (a medical catastrophe of worldwide dimensions) . Am J Kidney Dis . 1999;34:795–808
  2. Parving HH , Andersen AR , Smidt UM , Hommel E , Mathiesen ER , Svendsen PA . Effect of antihypertensive treatment on kidney function in diabetic nephropathy . Br Med J (Clin Res Ed) . 1987;294:1443–1447
  3. Hasslacher C , Bostedt-Kiesel A , Kempe HP , Wahl P . Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients . Diabetologia . 1993;36:1051–1056
  4. Fried L , Orchard T , Kasiske B  Lipids and Renal Disease Progression Meta-analysis Study Group . Effect of lipid reduction on the progression of renal disease (a meta analysis) . Kidney Int . 2001;59:260–269
  5. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  6. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  7. Chantrel F , Enache I , Bouiller M , et al.   Abysmal prognosis of patients with type 2 diabetes entering dialysis . Nephrol Dial Transplant . 1999;14:129–136
  8. Dunn EJ , Burton CJ , Feest TG . The care of patients with diabetic nephropathy (audit, feedback, and improvement) . QJM . 1999;92:443–449
  9. Ellrodt G , Cook DJ , Lee J , Cho M , Hunt D , Weingarten S . Evidence-based disease management . JAMA . 1997;278:1687–1692
  10. Feest TG , Dunn EJ , Burton CJ . Can intensive treatment alter the progress of established diabetic nephropathy to end-stage renal failure? . QJM . 1999;92:275–282
  11. Joss N , Paterson KR , Deighan CJ , Simpson K , Boulton-Jones JM . Diabetic nephropathy (how effective is treatment in clinical practice?) . QJM . 2002;95:41–49
  12. American Diabetes Association . Position statement. Diabetic nephropathy . Diabetes Care . 2002;25:s85–s89
  13. Kaplan E , Meier P . Nonparametric estimation for incomplete observations . J Am Stat Assoc . 1958;53:457–481
  14. Cox DR . Regression models and life-tables . J R Stat Soc Ser B . 1972;34:187–202
  15. Altman DG , Andersen PK . Calculating the number needed to treat for trials where the outcome is time to an event . Br Med J . 1999;319:1492–1495
  16. Kreft I , de Leeuw J . Introducing Multilevel Modeling . 1st edn.. London, UK: SAGE Publications Ltd; 1998;
  17. Morrish NJ , Wang SL , Stevens LK , Fuller JH , Keen H . Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes . Diabetologia . 2001;44(9 Suppl 2):S14–S21
  18. American Diabetes Association . Position statement. Standards of medical care for patients with diabetes mellitus . Diabetes Care . 2002;25:s33–s49
  19. Rimmer JM , Horn JF , Gennari FJ . Hyperkalemia as a complication of drug therapy . Arch Intern Med . 1987;147:867–869
  20. Hricik DE , Browning PJ , Kopelman R , Goorno WE , Madias NE , Dzau VJ . Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney . N Engl J Med . 1983;308:373–376
  21. Cagliero E , Levina EV , Nathan DM . Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients . Diabetes Care . 1999;22:1785–1789
  22. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) . Br Med J . 1998;317:703–713
  23. Hansson L , Zanchetti A , Carruthers SG , et al.  HOT Study Group   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension (principal results of the Hypertension Optimal Treatment (HOT) randomised trial) . Lancet . 1998;351:1755–1762
  24. Morris LS , Schulz RM . Patient compliance—an overview . J Clin Pharm Ther . 1992;17:283–295
  25. Oliveria SA , Lapuerta P , McCarthy BD , L’Italien GJ , Berlowitz DR , Asch SM . Physician-related barriers to the effective management of uncontrolled hypertension . Arch Intern Med . 2002;162:413–420
  26. Bogden PE , Abbott RD , Williamson P , Onopa JK , Koontz LM . Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension . J Gen Intern Med . 1998;13:740–745
  27. Keane WF , Polis A , Wolf D , Faison E , Shahinfar S . The long-term tolerability of enalapril in hypertensive patients with renal impairment . Nephrol Dial Transplant . 1997;12(Suppl 2):75–81
  28. Wang Y , Ng MC , So WY , et al.   Prognostic effect of insertion/deletion polymorphism of the ace gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes . Diabetes Care . 2005;28:348–354
  29. Benson K , Hartz AJ . A comparison of observational studies and randomized, controlled trials . N Engl J Med . 2000;342:1878–1886
  30. Concato J , Shah N , Horwitz RI . Randomized, controlled trials, observational studies, and the hierarchy of research designs . N Engl J Med . 2000;342:1887–1892
  31. McKee M , Britton A , Black N , McPherson K , Sanderson C , Bain C . Methods in health services research. Interpreting the evidence (choosing between randomised and non-randomised studies) . Br Med J . 1999;319:312–315

PII: S0002-9343(05)00661-3

doi: 10.1016/j.amjmed.2005.07.050

The American Journal of Medicine
Volume 118, Issue 12 , Pages 1414.e21-1414.e27 , December 2005

Article Tools

* Image Usage & Resolution